Durvalumab: tested on its own

110 studies: no other medicine in its arm. Page 2 of 2. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal CancerCompletedNCT03102047Phase 2Report a problem
• A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical ResectionWithdrawnNCT03038477Phase 2Report a problem
• Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung CancerTerminatedNCT03030131Phase 2Report a problem
• Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate CancerWithdrawnNCT02966587Phase 2Report a problem
• Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)WithdrawnNCT02885727Phase 2Report a problem
• Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02871323Phase 1Report a problem
• A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent GlioblastomaCompletedNCT02866747Phase 1/2Report a problem
• Durvalumab in Pediatric and Adolescent PatientsCompletedNCT02793466Phase 1Report a problem
• Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast CancerCompletedNCT02685059Phase 2Report a problem
• Adjuvant Durvalumab for Esophageal CancerStatus unknownNCT02520453Phase 2Report a problem

← Durvalumab